Semaglutide vs Retatrutide in Delray Beach: Which GLP-1 Is Right for You?

Let us settle the most important part first, because it changes the whole comparison: semaglutide is an approved, widely prescribed medication you can start in Delray Beach this month. Retatrutide is an investigational drug still working through late-stage clinical trials. It is not FDA-approved and it is not legitimately available outside a trial.

That distinction matters because retatrutide's trial results have generated genuine excitement, and where there is excitement there are clinics and websites willing to sell something they should not. Below is what each drug actually does, what the data shows, and what the sensible move is if you want to start losing weight now rather than in 2027.

How These Drugs Work — and Why the Difference Matters

Your gut releases hormones after you eat that tell your brain you have had enough, slow the rate at which your stomach empties, and prompt the pancreas to release insulin appropriately. In people carrying significant excess weight, that signalling is often blunted.

Semaglutide is a single-agonist. It mimics one of those hormones, GLP-1. That single mechanism produces reduced appetite, slower gastric emptying and better glycaemic control.

Tirzepatide is a dual-agonist, hitting both GLP-1 and GIP receptors. The addition of GIP appears to improve fat metabolism and, in head-to-head trial data, produces greater average weight loss than semaglutide.

Retatrutide is a triple-agonist — GLP-1, GIP and glucagon. The glucagon receptor is the novel part: rather than only reducing intake, it appears to increase energy expenditure. That is a genuinely different lever, and it is why the phase 2 results drew so much attention.

What the Trial Data Actually Shows

Semaglutide at weight-management dosing produced average total body weight reduction in the mid-teens as a percentage over roughly 68 weeks in its pivotal trial, with a substantial share of participants exceeding 20%. That is a well-replicated result across a large population and several years of real-world use.

Tirzepatide's pivotal weight-management trial produced higher averages still, in the low-to-mid twenties as a percentage at the highest dose over 72 weeks.

Retatrutide's phase 2 results were higher again at 48 weeks, and notably the weight-loss curve had not clearly plateaued by the end of the study. That is a striking signal. It is also phase 2 data in a smaller population, and the phase 3 programme is what will determine the real-world efficacy and safety profile.

Three caveats are worth stating plainly. Trial averages are not individual guarantees. All of these trials paired medication with lifestyle intervention. And a bigger number in a press release is not the same as the right drug for a specific patient.

Availability: The Part That Decides This for Most People

Semaglutide is available now, has years of post-marketing safety data, and is what the overwhelming majority of medical weight loss patients in Delray Beach are actually prescribed. Tirzepatide is likewise available.

Retatrutide is not approved and is not commercially available. Any clinic or website offering to sell you retatrutide today is offering an unapproved product from an unregulated source, with no guarantee of what is in the vial. We have written separately about what Delray Beach patients should know about retatrutide, and the summary is: it is worth watching, and it is not worth buying from a grey-market supplier.

If you want to be an early adopter legitimately, the route is enrolling in a clinical trial, not ordering online.

Side Effects and Tolerability

All three drugs share a gastrointestinal side-effect profile: nausea, constipation or diarrhoea, reflux and reduced appetite. These are usually dose-dependent, worst in the first weeks after each dose escalation, and manageable with slower titration.

The mechanism that makes retatrutide interesting — glucagon agonism — also increases heart rate somewhat and warrants closer cardiovascular monitoring. That is precisely the sort of question phase 3 exists to answer.

Across the GLP-1 class, the more consequential clinical issue is not nausea but lean mass. A meaningful fraction of the weight lost on these drugs is muscle, and muscle loss is exactly what you do not want if you intend to keep the weight off. This is why we run an InBody body composition scan at baseline and at intervals, and why protein intake and resistance training are part of the protocol rather than optional advice.

The Other Half of the Conversation: Loose Skin and Hormones

Two things routinely surprise patients partway through a GLP-1 protocol. The first is skin laxity after significant weight loss, which is common enough that we address it proactively rather than reactively — see our page on skin tightening after weight loss.

The second is that weight loss frequently unmasks or worsens an underlying hormonal issue, or that an existing hormonal issue is what stalls progress in the first place. If you plateau on a GLP-1 despite good adherence, thyroid and sex hormone panels are usually the next place to look rather than a dose increase. Our hormone replacement program and weight-loss program are coordinated for exactly this reason.

Medical Weight Loss at AmpUp Wellness in Delray Beach

Our semaglutide and GLP-1 weight loss program is supervised by David Patterson, APRN, with more than twenty years of clinical experience. Every patient starts with baseline labs and a body composition scan, follows a titration schedule designed to minimise side effects, and is reassessed on a defined cadence rather than left to refill indefinitely.

We see patients from Delray Beach, Boca Raton, Boynton Beach and across Palm Beach County. Our broader medical weight loss program covers the full picture: medication, body composition tracking, nutrition and the hormonal factors that determine whether the loss holds.

What the First 12 Weeks on Semaglutide Actually Look Like

Semaglutide is started at a low dose and stepped up on a fixed schedule, conventionally about every four weeks. The titration is deliberately gradual, and it is worth understanding why. Gastrointestinal side effects track how quickly the dose changes far more closely than they track the dose itself, and escalating faster does not produce faster weight loss. It produces nausea — and nausea is the single most common reason people abandon a protocol that would otherwise have worked.

Weeks one to four. The first thing most patients notice is not the scale but appetite: meals finish sooner, second helpings stop appealing, and the background food noise quietens down. If side effects appear, they cluster in the two or three days after each escalation. The mitigations are unglamorous and genuinely effective — smaller portions, lower-fat meals, eating slowly, stopping at comfortable rather than full, and drinking more water than feels necessary.

Weeks four to eight. Loss usually becomes steadier and more predictable here, and this is the window where what you do outside the medication starts to determine the quality of the result. Protein intake and resistance training are what decide how much of the weight coming off is fat and how much is muscle. Patients who ignore both still lose weight. They just lose a worse composition of it, and they are the ones most likely to regain it later.

Weeks eight to twelve. This is the first reassessment worth acting on: repeat labs, a repeat body composition scan, and a dose decision. Hold at the current dose if the response is good and tolerability is fine, step up if progress has genuinely stalled, or step down if side effects are affecting your daily life. Twelve weeks is early enough to correct course and long enough for the data to mean something.

Who Should Not Take a GLP-1

These are effective drugs and they are not appropriate for everyone. Some of the exclusions are firm, others simply mean the conversation has to be more careful and the monitoring closer. Either way, they are the reason a prescription should follow a proper consultation rather than an online questionnaire.

• Personal or family history of medullary thyroid carcinoma, or MEN2. This is a labelled contraindication for the GLP-1 class, based on thyroid C-cell tumours seen in rodent studies. It is a firm no rather than a discussion.
• A history of pancreatitis. Pancreatitis has been reported with these medications, so a prior episode changes the risk calculation and usually points toward a different approach.
• Active, severe gastroparesis. GLP-1 drugs slow gastric emptying by design, which makes an existing motility disorder worse.
• Pregnancy, breastfeeding, or actively trying to conceive. These medications are not used in pregnancy, and they are typically stopped well in advance of a planned conception.
• Insulin or a sulfonylurea in your current regimen. Not a bar to treatment, but doses of those medications often need adjusting downward, because combining them with a GLP-1 raises the risk of hypoglycaemia.

None of this is a reason to talk yourself out of asking. It is the reason to ask a clinician rather than a website. Screening for exactly these things — alongside your labs, your medication list and your history — is what the initial consultation is for.

What to Do Now

If you are choosing between starting semaglutide this month and waiting for retatrutide, the honest answer is that waiting costs you a year or more of progress for a drug whose real-world profile is not yet established. Starting a supervised GLP-1 protocol now does not close the door on switching later — patients move between agents routinely as availability and response change.

Book a consultation with David Patterson, APRN and we will look at your labs, your history and your goals, then recommend the option that fits — including telling you if medication is not the right first step.

Frequently Asked Questions

Is retatrutide available in Delray Beach?

No. Retatrutide has not been approved by the FDA and is not commercially available anywhere in the United States. Any seller offering it is supplying an unapproved product outside the regulated supply chain, with no assurance of purity, sterility or dose.

Is retatrutide better than semaglutide?

Phase 2 data showed greater average weight loss than semaglutide's trial results, but they are different studies in different populations, and phase 3 results will determine the real comparison. The practical answer today is that semaglutide is the better option because it is the one you can actually be prescribed and monitored on.

How much weight can I expect to lose on semaglutide in Delray Beach?

Pivotal trial data showed average total body weight reduction in the mid-teens as a percentage over roughly 68 weeks, with meaningful variation between individuals. Results depend heavily on adherence, protein intake, resistance training and whether underlying hormonal issues are addressed.

What is the difference between semaglutide and tirzepatide?

Semaglutide acts on the GLP-1 receptor alone; tirzepatide acts on both GLP-1 and GIP. Trial data shows greater average weight loss with tirzepatide, though tolerability, cost and individual response all factor into which one is prescribed.

Will I regain the weight if I stop?

Partial regain is common after discontinuation, which is why the protocol matters as much as the prescription. Preserving lean mass during the loss phase, building sustainable eating habits and correcting hormonal drivers all improve the odds of holding the result. We plan the exit from the medication, not just the entry.

Do I need bloodwork before starting a GLP-1?

Yes. Baseline labs screen for contraindications, establish thyroid and metabolic status, and give us a comparison point for follow-up. We pair them with an InBody scan so we can distinguish fat loss from muscle loss rather than guessing from the scale.